Is CLLS or CRDF more undervalued in 2026?

CirclFi compares Cellectis S.A. (CLLS) and Cardiff Oncology, Inc. (CRDF) using 13 institutional-grade valuation models. CLLS has a Quality of Company score of 2.5/10 while CRDF scores 5.9/10.

Which is a better buy — CLLS or CRDF?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CLLS and CRDF valuations compare?

CLLS at $3.52 and CRDF at $1.90 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CLLS vs CRDF Valuation Comparison 2026 — Intrinsic Value Analysis

CLLS

Biological Products, (No Diagnostic Substances)

Cellectis S.A.

Quality

2.5

out of 10

Value Trap

SAFE

Price

$3.52

Last close

Models

11/13

Active

CRDF

Biological Products, (No Diagnostic Substances)

Cardiff Oncology, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$1.90

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CLLS Fair Value	CLLS Upside	CRDF Fair Value	CRDF Upside
Bayesian DCF	Intrinsic	$0.93	-73.7%	$0.57	-70.2%
Earnings Power Value	Intrinsic	$1.52	-61.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.10	-97.4%	$0.06	-96.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLLS vs CRDF — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLLS vs CRDF — Which Stock Is More Undervalued?

CRDF scores higher with a 5.9/10 quality rating vs CLLS's 2.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cellectis S.A. (CLLS) and Cardiff Oncology, Inc. (CRDF) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLLS currently trades at $3.52 with a QOC of 2.5/10, while CRDF trades at $1.90 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).